Overview
Düsseldorf, August 5, 2025 – McDermott Will & Schulte advised APONTIS PHARMA AG on all corporate and capital market law issues concerning the preparation and execution of its Annual General Meeting on July 29, 2025.
At the Annual General Meeting, a resolution was passed by a large majority to transfer the shares of the minority shareholders to the main shareholder, Zentiva AG, in return for a cash payment of €10.40 per share (a so-called merger squeeze-out).
APONTIS PHARMA AG is a leading pharmaceutical company in Germany specialising in single-pill combinations that combine several active ingredients in one preparation and enable improved therapy adherence.
McDermott has regularly advised the company on corporate and capital market law issues since its initial public offering in 2021. The 2025 virtual Annual General Meeting took place at McDermott’s Düsseldorf office, as it has in previous years.
The McDermott team consisted of partner Philipp Grenzebach and associate Annabelle Juliette Rau.
About Us
Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.
